PMS and PMDD are not the same thing, and only one has strong drug evidence

The everyday word "PMS" and the clinical diagnosis "PMDD" describe two different things, and the distinction changes what the evidence says will help. Premenstrual syndrome is the broad, common experience of physical and mood symptoms in the two weeks before a period; premenstrual dysphoric disorder is its severe, predominantly psychological form, and it is the one for which a specific drug class — selective serotonin reuptake inhibitors — has the strongest trial evidence [s1] [s2].

What separates one from the other

The defining feature of premenstrual syndrome is timing, not any single symptom: the complaints appear only during the luteal phase, the roughly two weeks leading up to menstruation, and lift once bleeding begins [s1]. Most people who menstruate report some version of this. What marks out premenstrual dysphoric disorder is severity and character — the symptoms are dominated by mood rather than the body.

A cross-sectional study of 45,160 Brazilian women aged 20 to 49, recruited across 303 private clinics, put the prevalence of PMDD at 3.57% (95% confidence interval 3.40 to 3.75) [s2]. In that population the most frequently reported premenstrual symptoms were psychoemotional rather than physical: anxiety or tension was reported by 99.9% of women with symptoms and irritability or anger by 99.8%, while the most common somatic complaints, weight gain and oedema, were reported by 92.5% and 92.1% [s2]. The pattern is the point — PMDD sits at the mood-heavy end of the premenstrual spectrum, which is also why an antidepressant class turns out to be the best-studied treatment for it.

The treatment with real evidence: SSRIs

A Cochrane systematic review pooled the randomised trials of SSRIs against placebo in women with a prospective diagnosis of PMS, PMDD or late luteal phase dysphoric disorder [s1]. It found SSRIs reduced premenstrual symptoms more effectively than placebo. Pooling the studies that reported end scores, moderate-dose SSRIs produced a standardised mean difference of -0.65 (95% CI -0.46 to -0.84), across nine studies and 1,276 women — a moderate effect [s1]. Pooling the studies that reported change scores gave a smaller effect, a standardised mean difference of -0.36 (95% CI -0.20 to -0.51), across four studies and 657 women [s1].

Two practical findings sit inside that result. First, the drugs worked whether taken continuously or only during the luteal phase, with no clear evidence that one schedule beat the other — though the review notes that few studies compared the two head to head, so this is not settled [s1]. Second, the review graded its own evidence as low to moderate quality, the main weakness being poorly reported trial methods [s1]. This is a genuine effect, but it rests on an imperfect literature.

The other half of the ledger: adverse effects

The same review is direct about the cost. Withdrawals due to adverse effects were significantly more likely in the SSRI groups than on placebo (moderate dose: odds ratio 2.55, 95% CI 1.84 to 3.53, across 15 studies and 2,447 women) [s1]. The most common side effects at a moderate dose, expressed as the number of women who would need to take the drug for one additional person to experience the effect, were nausea (one in every 7), reduced energy or asthenia (1 in 9), somnolence (1 in 13), fatigue (1 in 14), decreased libido (1 in 14) and sweating (1 in 14) [s1]. Adverse effects were dose-related [s1].

That trade-off — a moderate benefit against frequent, dose-dependent side effects — is exactly the kind of information the popular framing of "PMS" tends to flatten. Whether it is worth it is a decision for a person and their clinician, made against the severity of the symptoms being treated. The evidence supports the drugs working; it does not tell any individual that the exchange is worthwhile for them.

What the evidence does not cover

The Cochrane review is about SSRIs, so it says nothing about the many other things marketed for premenstrual symptoms — supplements, dietary changes, and lifestyle regimens — which have their own, generally thinner, evidence bases and are not assessed here. It is also a review of symptom reduction, not of diagnosis: a prospective symptom diary across at least one cycle, not a single clinic conversation, is how PMDD is distinguished from other conditions that worsen premenstrually, and the studies here enrolled women who had that prospective confirmation [s1].

The honest summary is narrower than either the dismissive version ("everyone gets PMS") or the pharmaceutical version ("there's a pill for it"). PMS is common and mostly mild; PMDD is a distinct, severe, mood-dominated condition affecting a few per cent of women; and for that severe form, SSRIs have real but moderate evidence behind them, alongside side effects that are common enough to matter.

This article is informational and is not medical advice. Diagnosis of a premenstrual disorder, and any decision about medication, belongs with a qualified clinician.